Sagimet Biosciences (NASDAQ:SGMT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Sagimet Biosciences (NASDAQ:SGMT) had its price target upped by research analysts at Citizens Jmp from $12.00 to $29.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 212.50% from the stock’s previous close.

A number of other analysts also recently issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Sagimet Biosciences in a report on Friday. Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Friday, July 17th. Canaccord Genuity Group upped their price objective on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim cut their price objective on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Sagimet Biosciences Stock Down 1.2%

NASDAQ:SGMT opened at $9.28 on Friday. The stock has a market cap of $302.34 million, a P/E ratio of -7.25 and a beta of 3.37. The business’s 50-day moving average price is $7.44 and its two-hundred day moving average price is $6.54. Sagimet Biosciences has a twelve month low of $4.50 and a twelve month high of $10.01.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). On average, equities research analysts expect that Sagimet Biosciences will post -1.17 EPS for the current fiscal year.

Insider Transactions at Sagimet Biosciences

In other news, insider Elizabeth Rozek sold 10,545 shares of the company’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $81,829.20. Following the completion of the sale, the insider owned 224,414 shares of the company’s stock, valued at approximately $1,741,452.64. This represents a 4.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total transaction of $201,049.70. Following the transaction, the director directly owned 62,161 shares in the company, valued at approximately $618,501.95. This represents a 24.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 113,646 shares of company stock worth $920,491. 11.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its stake in shares of Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after acquiring an additional 4,391 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Sagimet Biosciences in the 4th quarter worth approximately $30,000. Bank of America Corp DE lifted its position in Sagimet Biosciences by 81.8% in the second quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock valued at $76,000 after purchasing an additional 4,473 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Sagimet Biosciences during the fourth quarter valued at approximately $62,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Sagimet Biosciences in the third quarter worth approximately $95,000. 87.86% of the stock is owned by institutional investors.

Trending Headlines about Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne trial: The FDA cleared Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of denifanstat, an oral, once-daily fatty acid synthase inhibitor for moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. The clearance removes a key regulatory obstacle and gives investors a clearer development timeline. Sagimet FDA Phase 3 trial announcement
• Positive Sentiment: Analyst raises price target: Canaccord Genuity maintained a “buy” rating and lifted its price target from $49 to $56, reflecting a highly bullish view of Sagimet’s clinical pipeline and potential commercial opportunity. Other analysts also maintain generally favorable ratings, supporting positive investor sentiment. Canaccord price target report
• Neutral Sentiment: Important execution risks remain: Denifanstat’s U.S. Phase 3 program depends partly on encouraging results from trials conducted by licensing partner Ascletis in China. Sagimet must still demonstrate efficacy and safety in U.S. patients, complete the trial and secure regulatory approval before generating potential product revenue.
• Negative Sentiment: Loss estimates revised lower: HC Wainwright reduced its fourth-quarter 2026 EPS forecast to a loss of $0.32 from $0.30. Sagimet also recently reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 consensus estimate, underscoring its continued dependence on financing while clinical programs advance.
• Negative Sentiment: Director sells shares: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although insider sales can be routine, the transaction may weigh on sentiment because it represents reduced personal exposure by a company director. George Kemble insider sale report

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.